Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ARTL

Artelo Biosciences Inc

May 16 • 04:00PM ET

1.36

Dollar change +0.04
Percentage change 3.02	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.13	Insider Own	0.83%	Shs Outstand	3.23M	Perf Week	-2.16%
Market Cap	4.39M	Forward P/E	-	EPS next Y	-0.95	Insider Trans	0.00%	Shs Float	3.20M	Perf Month	3.42%
Income	-9.60M	PEG	-	EPS next Q	-0.78	Inst Own	0.77%	Short Float	0.15%	Perf Quarter	-21.39%
Sales	0.00M	P/S	-	EPS this Y	37.26%	Inst Trans	37.19%	Short Ratio	0.37	Perf Half Y	3.82%
Book/sh	2.95	P/B	0.46	EPS next Y	51.52%	ROA	-66.62%	Short Interest	0.00M	Perf Year	-19.22%
Cash/sh	2.36	P/C	0.58	EPS next 5Y	-	ROE	-70.68%	52W Range	1.15 - 2.98	Perf YTD	-2.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.34%	ROI	-99.70%	52W High	-54.36%	Beta	1.29
Dividend TTM	-	Quick Ratio	11.36	Sales past 5Y	0.00%	Gross Margin	-	52W Low	18.26%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	11.36	EPS Y/Y TTM	13.31%	Oper. Margin	0.00%	RSI (14)	49.18	Volatility	5.83% 5.76%
Employees	6	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.50
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-2.32%	Payout	-	Rel Volume	0.15	Prev Close	1.32
Sales Surprise	-	EPS Surprise	20.41%	Sales Q/Q	-	Earnings	May 13 BMO	Avg Volume	13.26K	Price	1.36
SMA20	2.33%	SMA50	-4.79%	SMA200	-9.22%	Trades		Volume	1,969	Change	3.02%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-21	Initiated	Ladenburg Thalmann	Buy	$7

May-13-24 01:53PM	ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-10-24 09:00AM	Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th (GlobeNewswire)
Apr-23-24 08:30AM	Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy (GlobeNewswire)
Apr-22-24 08:30AM	Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time (GlobeNewswire)
01:53PM	Loading…
Mar-25-24 01:53PM	ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023 (InvestorPlace)
08:00AM	Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 09:15AM	Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge (GlobeNewswire)
Feb-15-24 09:00AM	Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th (ACCESSWIRE) +6.13%
Jan-23-24 08:30AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy (GlobeNewswire)
Jan-08-24 08:30AM	Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12 (GlobeNewswire)
Dec-05-23 08:30AM	Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire)
Nov-30-23 09:00AM	Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire)
Nov-13-23 08:00AM	Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-23 09:00AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers (GlobeNewswire) -8.33%
08:30AM	Loading…
Nov-02-23 08:30AM	Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023 (GlobeNewswire)
Oct-04-23 08:30AM	Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia (GlobeNewswire)
Sep-13-23 08:30AM	Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th (GlobeNewswire)
Sep-07-23 08:00AM	Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12 (GlobeNewswire) -22.60%
Sep-06-23 09:00AM	Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th (GlobeNewswire) +27.03%
Sep-05-23 09:00AM	Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th (GlobeNewswire)
Aug-10-23 08:00AM	Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-19-23 09:00AM	Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023 (GlobeNewswire)
Jul-10-23 08:30AM	Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11 (GlobeNewswire)
Jun-28-23 08:30AM	Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-27-23 08:30AM	Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-26-23 08:30AM	Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-07-23 08:30AM	Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire) +10.26%
May-11-23 08:00AM	Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-23 08:30AM	Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire) -21.75%
08:00AM	Loading…
Mar-31-23 08:00AM	Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update (GlobeNewswire) +7.91%
Feb-15-23 08:30AM	Artelo Biosciences to Present at MicroCap Rodeos Annual Winter Wonderland Best Ideas Virtual Investor Conference on February 22, 2023 (ACCESSWIRE)
Feb-02-23 09:00AM	Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire)
Jan-26-23 08:30AM	Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd (GlobeNewswire)
Nov-08-22 08:00AM	Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-18-22 08:30AM	Artelo Biosciences to Present at The LD Micro Main Event XV (Newsfile)
Sep-22-22 09:00AM	Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th (GlobeNewswire)
Sep-07-22 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 09:00AM	Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5 (GlobeNewswire) +45.87%
Aug-09-22 08:10AM	Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -23.66%
Jul-19-22 09:07AM	Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire)
Jun-27-22 08:30AM	Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain (GlobeNewswire)
Jun-24-22 08:30AM	Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland (GlobeNewswire)
Jun-01-22 08:30AM	Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th (GlobeNewswire)
May-16-22 01:20PM	36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 (ACCESSWIRE)
08:55AM	Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th (GlobeNewswire)
May-13-22 08:30AM	Artelo Biosciences to Present at MicroCap Rodeos Spring into Action Best Ideas Virtual Conference on May 16th (ACCESSWIRE)
May-12-22 08:30AM	Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +7.69%
Apr-26-22 07:33AM	Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York (Newsfile)
Apr-25-22 07:30AM	Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York (Newsfile)
Apr-13-22 08:30AM	Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia (GlobeNewswire) +20.38%
Mar-28-22 09:25AM	Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer (GlobeNewswire) -7.34%
Mar-22-22 09:00AM	Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th 30th (GlobeNewswire)
Mar-21-22 08:30AM	Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update (GlobeNewswire) +7.27%
Mar-02-22 08:30AM	Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol (GlobeNewswire) +14.30%
Jan-12-22 08:30AM	Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jan-11-22 08:30AM	Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom (GlobeNewswire)
Jan-10-22 09:00AM	Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire) -8.00%
Jan-04-22 01:38PM	Lvm Capital Management Ltd Buys Medtronic PLC, Zoetis Inc, Eaton Corp PLC, Sells AT&T Inc, ... (GuruFocus.com)
Nov-29-21 08:30AM	Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update (GlobeNewswire) -6.95%
Nov-11-21 08:30AM	Artelo Biosciences to Present at the Q4 Investor Summit on November 17th (Newsfile) -7.45%
Nov-02-21 07:33AM	We Think Artelo Biosciences (NASDAQ:ARTL) Needs To Drive Business Growth Carefully (Simply Wall St.) +14.93%
Sep-08-21 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-11-21 04:18PM	Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th (Newsfile)
Aug-04-21 08:30AM	Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines (GlobeNewswire)
Jul-21-21 08:30AM	Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences CAReS Study on July 28, 2021 (GlobeNewswire)
Jul-12-21 08:30AM	Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Jul-07-21 08:30AM	Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th (GlobeNewswire) -8.55%
Jun-22-21 08:00AM	Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium (GlobeNewswire)
Jun-02-21 08:30AM	Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th (GlobeNewswire)
May-06-21 07:00AM	Artelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021 (Newsfile)
May-04-21 08:00AM	Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors (PR Newswire) -5.84%
Apr-20-21 02:02AM	We're Hopeful That Artelo Biosciences (NASDAQ:ARTL) Will Use Its Cash Wisely (Simply Wall St.) -9.52%
Apr-13-21 08:30AM	Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Apr-12-21 08:30AM	Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire) -9.21%
Mar-19-21 10:00AM	Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development (GlobeNewswire)
Mar-11-21 07:10AM	Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd (GlobeNewswire)
Mar-09-21 08:30AM	Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors (GlobeNewswire) +22.37%
Mar-02-21 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th (GlobeNewswire) -6.10%
Feb-17-21 08:30AM	Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal (GlobeNewswire) +14.18%
Feb-16-21 08:30AM	Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer (GlobeNewswire)
Feb-12-21 10:56AM	ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today (InvestorPlace) +63.19%
Feb-08-21 08:30AM	Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants (GlobeNewswire) +8.47%
Feb-02-21 08:30AM	Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia (GlobeNewswire) +20.19%
Jan-29-21 04:05PM	Artelo Biosciences to Present at the LSX World Congress Virtual Conference (GlobeNewswire) +6.39%
Jan-14-21 08:30AM	Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Jan-05-21 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference (GlobeNewswire)
Dec-09-20 08:30AM	Artelo Biosciences Files Patent Application for New Formulation of ART27.13 (GlobeNewswire) +11.69%
Dec-08-20 08:30AM	Artelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th (GlobeNewswire)
Dec-02-20 08:30AM	Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors (GlobeNewswire) +15.69%
Nov-23-20 08:30AM	Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs (GlobeNewswire)
Nov-16-20 08:30AM	Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire)
Nov-11-20 08:30AM	Artelo Biosciences to Present at the Virtual Fall Investor Summit on November 18th (ACCESSWIRE)
Nov-04-20 08:00AM	Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-20 05:48AM	Did Artelo Biosciences, Inc. (NASDAQ:ARTL) Insiders Buy Up More Shares? (Simply Wall St.) +5.18%
Oct-21-20 08:30AM	Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders (GlobeNewswire)
Oct-14-20 04:05PM	Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters Option (GlobeNewswire)
Oct-09-20 08:30AM	Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering (GlobeNewswire) -5.29%
Sep-29-20 08:00AM	Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia (GlobeNewswire) +11.26%
Sep-11-20 09:00AM	Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th (GlobeNewswire) -5.32%

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARTL

Artelo Biosciences Inc

Upgrade your FINVIZ experience